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ABSTRACT 
Synthesis of Phenothiazinium Derivatives 
by 
Selorm J. Fanah 
Photodynamic therapy (PDT) employs photosensitizing drugs for treating cancer.  Once 
introduced into the body and localized in tumor cells, these photosensitizers are irradiated with 
light to produce active singlet oxygen radicals which kill cancer cells. The current drugs used in 
PDT have low quantum yield and always require a high energy radiation (normally laser). There 
is always a need for more effective drugs that have a high quantum yield and can be activated by 
visible light, in order to eliminate side effects caused by laser radiations.  
In this work we synthesized derivatives of phenothiazine and phenothiazinium chromophores 
from the commercially available phenothiazine (1).  These derivatives include: 3,7-
dibromophenothiazinium perbromide (2), N-acetyl phenothiazine (5), N-acetyl-3,7-
dibromophenothiazine (6),  3,7-dinitrophenothiazine (10), N-acetyl-3,7-dinitrophenothiazine 
(11), N-acetyl-3,7-diaminophenothiazine (12), thionine chloride (15) and 3,7-
phenothiaziniumdinitrile (14). Synthesis of 3,7-phenothiazinium dicarboxylic acid was attempted 
using 1 and 15 as starting materials by exploring various synthetic routes for carboxylic acids. 
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CHAPTER 1 
INTRODUCTION 
 Developing alternative therapeutic ways of treating cancer and tumor cells have become 
an important field of study and much interest for scientists. Although chemotherapy has been 
widely used, its associated side effects and cost have paved way for photodynamic therapy. 3  
The key component of photodynamic therapy (PDT) is the use of a suitable drug 
(photosensitizer) that can absorb radiation at a specific wavelength.  However, there are 
limitations for the use of photosensitizers in PDT, such as poor absorptivity, contamination by 
other compounds, low photostability of the drug, toxicity, and the ability of the drug to be 
localized in neoplastic tissues.4,5 A good number of compounds and their analogues have been 
synthesized for this method over the last few decades. Among them are some phenothiazine 
derivatives which have shown distinctive characteristics in photo antimicrobial activities.5  
The primary purpose of this work is to synthesize derivatives of phenothiazine that 
satisfy most of the requirements mentioned above.  For example, a potential advantage of 
attaching a carboxylate group to phenothiazine is to convert the aromatic chromophore into one 
which would have a high singlet oxygen quantum yield when exposed to light.11, 17 Such 
derivatives can have further application in dye sensitized solar cells (DSSC), and syntheses of  
new generations of metal-organic frameworks (MOF’s). 
Photodynamic Therapy (PDT)  
Photodynamic therapy (PDT) employs drugs which are sensitive to light 
(photosensitizers) in the treatment of cancer cells. This treatment uses light rays of a specific 
wavelength in the treatment of the cells. The wavelength of the light used determines which parts 
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of the body with tumor cells can be treated. Also, the type of photosensitizers used at a time 
determines which wavelength of light to be used since each of the light sensitive drugs can only 
absorb photons produced at specific wavelengths of light.  When photosensitizers absorb 
photons, they are excited. These excited photosensitizers transfer energy to tissue oxygen which 
generates singlet oxygen to kill cancer cells.1-3 The light source for irradiating the cells can be 
from lasers which is directed through fiber optics to the affected areas during treatments.2 
Photosensitive agents which are introduced into the body by injection are absorbed into 
the blood streams by all body cells and tumor or cancer cells, but their life span in the cancer 
cells are much longer than the normal body cell due to their strong selective binding to cancer 
cells. This selective binding of photosensitizers to cancer cells is made possible by such features 
as a larger volume, larger fraction of macrophages, leaky microvasculature, poor lymphatic 
drainage, lower extracellular pH, larger amount of newly formed collagens, and numerous 
receptors for lipoprotein.6 
Approximately one or two days after they are introduced into the body, most of the drugs 
would leave the normal host cells but remain in higher concentrations in  tumor cells. These cells 
are then exposed to red light of a specific wavelength (600 nm) which activates the 
photosensitizing drugs to produce reactive singlet oxygen radicals that kill the cancer cells as 
shown in Figure 1.1,5 
In addition to killing cancer cells, this therapy appears to destroy and reduce the diameter of 
tumor cells through some other routes. The photosensitive drugs damage blood vessels of tumor 
cells cutting the supply of blood nutrients to them and also activate the body immune system to 
attack tumor cells.1-4 
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This breakthrough of treating cancer cells can be traced to the work of Rabb Oscar, a 
medical student of Prof. Herman Von Trappeiner in 1900.5 In his work, he noticed an elevated 
harmfulness of acridine orange towards paramicium in the presence of light. Von Trappeiner 
reported his first test for the treatment of skin carcinoma using eosin solution. He later named 
this method the photodynamic therapy (PDT) in 1943.5 
Despite the advantage of this method of treating cancer over chemotherapy, it has a few 
limitations. Undoubtedly, one of these limitations is the small number of photosensitizing drugs 
available in the market.3 
 
Figure 1:  The mechanism of action for Photodynamic Therapy.5                   
    
Photosensitizers 
Photosensitizing agents are compounds that can activate singlet oxygen upon exposure to 
light of a specific wavelength at which the compound can absorb. The wavelength of operating 
light for PDT ranges between 600 nm to 900 nm.6   Light of wavelength below 600 nm tends to 
be absorbed by endogenous molecules such as hemoglobin; light of wavelength above 900 nm 
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does not produce enough reactive singlet oxygen radicals. Moreover, a light source with higher 
wavelength can penetrate body tissues more easily leading to severe side effects.6 
Although there are a number of photosensitive agents, only a few can be employed in 
PDT based on specific criteria which they need to meet. A photosensitizer needs to be nontoxic,  
highly soluble in lipids, produce a high amount of active singlet oxygen radicals when exposed 
to radiations (i.e., of a high quantum yield),8 selective towards hyper-proliferating tissues,7 and 
needs to be photostable.9 All these requirements need to be met for a photosensitizer to be used 
clinically.7-9 
  Some porphyrin derivatives have over the years been the most used photosensitizers for 
clinical PDT.10 Garbo, Keck and Selman reported in their work that dihematoporphyrin 
derivatives, which are widely used as photosensitizers for clinical photodynamic therapy, have 
poor absorption in the visible region; therefore there is a need for new photosensitizers.10    Other 
groups of photosensitizers include purpurins, porphycenes, pheophorbids, and most recently 
phenothiazine.11 
 
Phenothiazine 
Over the years, photosensitizers with phenothiazinium chromophore have found 
considerable use in PDT and photodynamic antimicrobial therapy (PACT). Phenothiazinium 
dyes, under the influence of light, are known to inhibit viral growth.18 The major compound of 
this group is methylene blue which is still used in most cancer treatments, photo disinfection of 
oral cavity, and blood plasma photo decontamination.12  
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Despite the useful effects of these lead compounds, developing other analogues with 
different side groups are slowly emerging.12 Work by Tiana et. Al., showed that the tissue 
absorption rate of some phenothiazine-based compounds is very high, and that some of these 
compounds can be used in dye-sensitized solar cells (DSSC).11, 17 Other useful derivatives of 
phenothiazine that are used in DSSC technology are thionine, azure C, and toluidine blue.11,12 
 
Methylene Blue 
           Methylene Blue (MB) is a phenothiazine derivative that contains two dimethyl amino 
groups. The dimethyl amino auxochromes and the phenothiazine chromophore make up the body 
of this dye. This lead compound and its derivatives have been used in drug research for treating 
various viral and bacterial infections.17  
           Methylene blue was part of the first group of drugs ever synthesized as an antiseptic for 
clinical therapy.17 This dye’s λ max values of 608 and 668 nm are within the suitable range of 
wavelength for PDT photosensitizers .16 Clinically, methylene blue (MB) is available as an 
aqueous solution (1% w/v; 10 g/ L or 26.7 mM), and the recommended dose is between 1 and 4 
mg per kg of body weight.15 
            Although this derivative of phenothiazine meets most of the requirements for application 
in PDT, its poor lipophilicity decreases its uptake by damaged and cancer cells. Therefore, any 
work leading to improving lipophilicity of methylene blue and increasing its ability to photo 
cleave DNA is considered attractive.19  
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Methylene blue 
 
Thionine 
Another name for thionine is Lauth’s violet. This metachromatic dye is mostly used in 
biological staining.13 It is sometimes used to mediate electron transfer in microbial fuel cells.13,14 
Thionine is used in place of Schiff’s reagent in the quantitative staining of the DNA.14 When 
both amines on the phenothiazine rings are methylated, the product is the widely known 
phenothiazinium compound methylene blue, and the intermediate compound is azure C 
(monomethyl thionine).14 
 
Thionine 
 
Basic Mechanism of Photosensitization 
              Photosensitization is a reaction that is initiated  by a light-absorbing molecule 
(photosensitizer) which is capable of transferring energy to other species.30 Molecules used in 
this reaction must absorb photons before they can have an effect in their environment. In some 
instances, the light-absorbing molecules are chemically altered after the absorption of photons, 
but they do not   react with other molecules in the system.30  
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             On the other hand, in some cases, there are alterations of other molecules (substrate or 
acceptor) in the system after photons or light have been absorbed by the photosensitizers. This 
reaction can occur in living cells or tissues, or can take place in pure chemical systems.30 PDT is 
much concerned with the reaction of light-absorbing species in the living cells and tissues.  
            The process is initiated by excitation of photosensitizers (D*) to energy rich states when 
photons are absorbed. These excited  photosensitizers have a half-life between 10-6 to 10-9 
seconds during which the excited molecules undergo internal reactions that ultimately lead to the 
alteration of the chemical nature of substrates.30 The molecules then either relax to the ground 
state via  fluorescence or via intersystem crossing to other excited energy states, usually the 
triplet states where the excited molecule tend to have a much longer half-life of 10-3 seconds.11,30 
It is the prolonged interaction of photosensitizers with tissue oxygen in the triplet excited state 
that generates high amounts of singlet oxygen  species; for destroying tumor cells. This occurs in 
one of two types of reactions as seen in Figure 2.11 
 
 
Figure 2: Reactions for the Type I vs Type II Photosensitization processes.11, 30-32 
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          Photosensitizer in the type I path reacts directly with the substrate to produce a radical or a 
radical ion in the substrate as well as the photosensitizer as a result of an electron transfer that 
takes place during the reaction process. The electron transfer can proceed from any of the 
reactants.  Photosensitizer usually accepts an electron from the substrate which results in the 
formation of a photosensitizer radical anion (D.-) and a substrate radical cation (Substrate.+).30,32 
When oxygen is present, these radicals further react to produce oxygenated molecules leading to 
the loss of the photosensitizer due to its conversion to the oxidized product. Regeneration of the 
original photosensitizer is also possible from the type I pathway, when there is a direct transfer 
of an extra electron from the photosensitive radical anion to oxygen to produce superoxide form 
of the radical anion (O2
.-).30,31 
           In pathway II, excess energy is transferred from the photosensitizer to a ground-state 
molecular oxygen (3O2) which is naturally in the triplet state to produce singlet oxygen species 
(1O2). The original form of photosensitizers in the ground-states are generated in this pathway as 
the excited singlet oxygen reacts with substrates to form oxidized products.30 
           These singlet oxygen species have a life span shorter than 0.01- 0.04 μs and diffusion 
distance between 0.01-0.02 μm per second.6,11 Quantum yields for lipophilic photosensitizers are 
much higher compared to hydrophilic ones due to the high diffusion rate of singlet oxygen in 
lipophilic photosensitizers.11 This high diffusion rate also makes them more selective in 
localization in cell and tissue parts with high lipid concentrations.11  
           Nuclear membranes, mitochondria, and reticulum lysosomes are typical examples of parts 
in living cells with higher concentrations of lipids where the photosensitizers can selectively 
accumulate to enhance apoptosis (cell death) when irradiated with red light.11 Photooxidation 
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further enhances apoptosis by activating phospholipase enzymes in cell membranes which 
ultimately results in dynamism in the permeability of cell membrane and inhibition other 
enzymes such as mitochondrial enzymes. This inhibition of cell enzyme action is believed to be 
the major cause of cell death in photodynamic therapy.11 
 
Metal Organic Frameworks (MOF) 
Metal Organic Frameworks (MOF’s) are porous crystalline compounds in 1, 2, or 3 
dimensional robust structures.24 These materials are formed from joining metal ions with organic 
linkers (dicarboxylic acids), using strong bonds to create a crystalline metal cluster with 
permanent porosity.24 Materials and crystals of high porosity and stability are of high importance 
because they allow other molecules to be trapped in these pores.25 These pore apertures control 
the size of molecules that may pass through by providing the surface and pore gaps to perform 
the desired functions.24,25 The challenge over the years has been the making of materials and 
crystals with pores suitable for trapping large organic, inorganic, and biological molecules.29 The 
largest reported aperture for a pore is 32 by 24 Å, and the largest internal pore diameter reported 
is 47 Å, both of which were present MOFs.28, 29 
This exceptional porosity of MOF’s makes them potential materials for many industrial 
applications such as gas storage, separation, and catalysis.25  They have become an extensive 
subject of study, specifically in the energy industries due to their high thermal stability and for 
their potential application in energy technologies such as fuel cells, super capacitors, and 
catalytic convertors.26 To maximize the storage capacity of gases in these highly porous 
crystalline materials, it is important to increase the number of absorptive sites within the MOF 
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structure.25,26 This can be achieved by modification of the organic linkers to give ultra-high 
porosity.     
   However, large linkers lead to fragile frameworks and to lattice interpenetrations which 
reduces the porosity.25, 26 The use of expanded linkers mixed with second linkers has resulted in 
stable frameworks with the highest known porosity and surface area.  MOFs have limitless future 
applications due to the porosity, larger surface area, adjustable compositions and tunable pore 
size.27 The surface area to volume makes them perfect to replace zeolites at every level when 
produced on a large scale.27 As solid structures produced from coupling of mechanical and 
chemical properties on molecular scale, MOF’s have very unique electrical properties which can 
be explored for production of energy on a large scale or even used as good electric conductors.25 
The pores on their surfaces also make them good and effective materials for drug loading.27 
 
MOF’s as Potential Drug Carriers 
 MOF’s have over the years been developed as capable materials for drug delivery, owing 
to their high porosity which enables high drug loading, versatile functionality, larger surface 
area, biodegradability, and chemical stability.27 Large amount of drug materials that are absorbed 
into pore apertures of MOFs including procainamide, ibuprofen, and nitric oxide can be released 
once they are introduced into the body (see Figure 3).27 
 Recent developments have seen MOF materials scaled down to nanosizes to serve as 
carriers for selective delivery in cisplatin prodrugs.27 Despite the remarkable improvement made 
in the use of MOF’s for delivery of drugs, many other feature developments must occur in order 
for them to become viable nano-therapeutic agents.27 Limitations of current therapeutics such as 
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poor pharmacokinetics, rapid clearance, high doses, and high side effects must see some 
advancement in disease treatment.27 Most of these limitations associated with small molecular 
drugs can be relieved by making use of novel systems from MOF’s which has improved 
characteristics such as biocompatibility, kinetics of drug release, high loading ability, size, and 
surface properties.27 
Moreover, these nanoparticles can specifically be designed to target tissues of certain 
disease (e.g. tumor and cancer cells) by conjugation present in targeting ligands.27 They can be 
engineered to contain agents which provide both imaging and therapy, which is much difficult to 
achieve in conventional therapeutic methods.27 Abraxane and Doxil demonstrate the clinical 
success of the nanoparticle therapeutic approach.27 
 
Figure 3: Formation of a 1D MOF and the loading of a drug material by physical encapsulation 
into the pore aperture of the MOF (modified from Huxford et. Al.).27 
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Dye-Sensitized Solar Cells (DSSC) 
DSSC (shown in Figure 4) are third generation solar cells based on a photo 
electrochemical system with a semiconductor formed between an electrolyte and a photo-
sensitized anode.34 They include Cadmium telluride (CdTe), Copper Indium Gallium Selenides 
solar cells (CIS or CIGS) and other amorphous solar cells.35  
The production cost of this solar cell concept compared to the traditional silicon and cells 
is predicted to be about five times lower, with a conversion efficiency of about 6-10% depending 
on the size and thickness of dye used.36 Although their construction is simple and less expensive, 
DSSC suffer some major challenges such as low efficiency, low scalability and low stability.37  
Factors such as internal resistance, open circuit voltage (Voc), short circuit current (Isc), 
and fill factor of dyes affect the efficiency of DSSC greatly.37 The current output of DSSC can be 
improved through the reduction of the internal resistance by modifying the roughness factor, 
adjusting the thickness of conducting layer and making the gaps between electrodes much 
smaller.36,37 The employment of chemically aggressive liquid electrolytes makes the use of silver 
fingers very difficult for current collection and also affect the upscale of the cell.37 
 
Operating Principle of DSSC 
The photo-electrode is coated with nanocrystalline TiO2 (Titanium Oxide) which is 
porous to provide a large surface area for adsorption of the photosensitive dye. This porous TiO2 
layer allows for charge transfer upon excitation. The quality of the TiO2 electrode significantly 
affects the efficiency of photo conversion in DSSC. When photons are absorbed, the molecules 
of the dye are excited from the ground state highest occupied molecular orbitals (HOMO) to the 
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excited states lowest unoccupied molecular orbital (LUMO) as shown in Figure 4. Once excited, 
electrons are injected into the conduction band of the nanostructured semiconductor TiO2 film, 
and transported between the oxide nanoparticles (refer to Figure 4).38, 39  
The transported electron is then extracted to a load where it delivers electrical energy as 
its work done.38 Once the injection of the electron occurs, the dye becomes oxidized.38 Injected 
electrons are replenished from the dye in the excited states from the electrolyte (3I- → I3- + 2e-) 
such as the iodide/triiodide couple (electrolyte). The couple receives electrons from an external 
circuit and is regenerated by reduction (I3
- + 2e- → 3I-) of the triiodide at the cathode38. In other 
words, the iodide-triiodide (I-/I3
-) couple electrolyte serves as an electron mediator between the 
TiO2 electrode and the counter electrode coated with carbon (see Scheme 1 and Figure 4).
38,39  
 Moreover, the dye molecules are regenerated from their oxidized form by accepting 
electrons from the redox I-/I3
- electron mediator.38,39 The internally donated electron which is 
injected to the oxide layer is substituted by electron from  I3
-
 which gets reduced to I
- ion 
(Scheme 1).39 Electric power generation in DSSC cause no permanent transformation in 
chemical composition. This is as a result of electron movements through the wider band gap 
present in the conduction band of the nanostructured semiconductor. This is accompanied by 
charge-compensating diffusion of cations in the electrolytic layer of the nanoparticle surface.39  
D + photon                   D*                                                          (Excitation process) 
D* + TiO2                          e
-
(TiO2) + D
+                                                                  (Injection process) 
 e- (TiO2) + C.E                         TiO2 + e
-
(C.E) + electrical energy     (Energy generation) 
 D+ + 
3
2
I-                       D + 
1
2
I-3                                                                             (Regeneration of Dye) 
 
1
2
 I-3    +       e-(C.E)                        
3
  2
I-   +   C. E                                                        (Electron Recapture)  
Scheme 1: Principal reactions that occur in DSSC.39 
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Figure 4: A typical structure of the DSSC (modified from Khalil et. Al.).39 
 
Sensitizers (Dyes) 
The most prominent and promising group of dyes used in DSSC are ruthenium (II) 
complexes and metal-free organic dyes.39 These Ru (II) complexes show high rates of charge 
transfer to ligand in the visible region of the electromagnetic spectrum; a pre-requisite for 
injecting electrons efficiently into the wide conduction band of the TiO2 semiconductor.
39  
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However, due to the scarcity of ruthenium, Ru dyes used in DSSC are very expensive.40 
Metal-free organic dyes, on the other hand, have high molar extinction coefficients, are less 
expensive, are flexible in molecular tailoring, and are environmentally compatible.40 Some of the 
metal-free organic dyes used extensively in studies for construction of dye moieties in DSSC 
include triphenylamine (TPA), carbazole, coumarins, indole-dye, porphyrin, and phenothiazine 
(PTZ).39,40  
Recent studies on phenothiazine-based sensitizers show promising improvement on the 
efficiency due to their electronic and structural properties.39,40 Anchor dyes of phenothiazine 
with strong electron withdrawing groups such as cyanides (CN) and carboxylic acids (-COOH) 
effectively inject electrons into the conduction band of the TiO2 due to the extension of their π-
system.40 This effective electron injection is further confirmed with calculations on the 
adsorption energies on the TiO2 surfaces after preferred anchoring configurations were 
established.40  
 
Catalytic Hydrolysis:  Role of Carboxylic Acids 
Carboxylic acid hydrolysis is depicted in all amino acids which play essential roles as 
building units of proteins and as intermediates in metabolism. For instance, certain conserved 
amino acid residues of protein tyrosine phosphatases (PTPases) are strongly involved in catalytic 
activities at the enzyme active site.42 Investigations of the role of aspartic acids confirmed its 
essential role in the enzyme’s catalytic activity. 42 
             Kinetic analysis by Lohse et. Al. on aspartic acid reactions with mammalian 
phosphatases at different pH suggests a phosphoryl group transfer, which leads to the hydrolysis 
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of dipeptide bonds.42 Other findings by Denu et. Al., in an efforts to understand the structure, 
function and biological properties of PTPases through kinetic analysis, showed that the aspartic 
acid residues were conserved and involved in a general acid catalytic mechanism.42 
 
General Acid-Base Ester Hydrolysis 
The partial transfer of a proton by a Bronsted acid to a reactant in the transition state 
denotes general acid catalysis, while the acceptance of the proton by a Bronsted base leads to an 
increase in the reaction rate which results in the basic catalysis.44 Side chains of aspartic and 
glutamic acids have considerable acidic and basic properties and would likely behave as catalysts 
in general acid-base reactions in cells. Hydrolysis of carboxylic acids and phosphate esters, 
carbonyl additions and amino lysis of esters are typical acid-base reactions of aspartic acids44.  
Also, due to the amphoteric nature of amino acids, aspartic acid readily undergoes 
nucleophilic and electrophilic reactions at different pH as shown in Figure 5 below. These 
properties make aspartic acid catalyze both acidic and basic reactions.44 
 
 
Figure 5: Tautomerism of aspartic acid at different pH. 
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General Acid Catalyzed Ester Hydrolysis 
The initial step in the proposed mechanism under acidic condition as shown in Scheme 2 
involves the abstraction of a proton from the protonated amino group (-NH2) in the aspartic acid 
(amino acid). This facilitates the nucleophilic attack of water on the carbonyl carbon with a 
corresponding proton transfer of proton between the water molecule and aspartic acid.43 This 
proton transfer step stabilizes the intermediate formed.43 Tautomerism between the alcohol group 
and carbonyl group easily releases the alkoxy group by proton abstraction from the protonated 
amino group of aspartic acid.  Finally in step 4, aspartic acid abstracts a proton which is 
transferred to water, leaving the carboxylic acid and alcohol formed as the final product.43 
 
 
Scheme 2: Proposed mechanism for the hydrolysis of esters by aspartic acid under acidic 
conditions. 43 
 
 
 31 
 
General Base Catalyzed Ester Hydrolysis 
The base catalyzed mechanism (Scheme 3) involves the addition of a nucleophile which 
is followed by the abstraction of a proton by the amino group from water while the water 
molecule in turn attack the carbonyl group of the ester.43   
 
 
Scheme 3: Proposed mechanism for the hydrolysis of esters by aspartic acid under basic 
conditions. 43 
 
Phosphodiester Bonds 
         Amino acids such as aspartic acid and glutamic acids have shown an ability to increase the 
rate of hydrolysis of many molecules because of their amphoteric nature.20 Phosphodiester bonds 
are found in every part of the biological systems.  They are essential to all life since they 
constitute the backbone of deoxyribonucleic acids (DNA), ribonucleic acids (RNA), and also 
exist in various parts of cell membranes (Figure 6).20  
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           In cellular membranes, phosphodiester bonds function as linkages in phospholipids.  
These linkages are strong covalent bonds existing in between phosphate groups and two ring 
pentoses over two ester bonds.21 The phosphodiester covalent bonds holding the pentose groups 
of DNA and RNA can be broken through alkaline hydrolysis through hydrophobic or hydrophilic 
interactions of the tail ends of polar groups present in their bonds.20,21  
 
T: Thymine 
A: Adenine 
Figure 6: A section of the DNA showing phosphodiester bonds. 20,21 
Phosphodiester bonds of RNA have received a lot of scientific interest over the years; 
further studies on the mechanism of their hydrolysis by enzymes are needed to provide more 
insight and to develop artificial enzyme models.44 The function of a base in hydrogen abstraction 
depicted by aspartate plays an essential role in the cleavage of the phosphodiester bonds of RNA 
(Scheme 4).44 A similar mechanism is the hydrolytic cleavage of the phosphodiester bonds of 
RNA and DNA.45 
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Scheme 4: Proposed hydrolysis of the phosphodiester bond of RNA by aspartate.45 
 
Research Objectives 
The major aim of this research is to synthesize selected phenothiazinium derivatives for 
potential applications in photodynamic therapy, DSSC, and MOFs technologies. Synthesis of 
phenothiazinium derivatives with two carboxylic acid side groups are of special interest for their 
relevance to hydrolytic enzymes that utilize carboxylic groups in their catalytic activities.  
Carboxylic groups are encountered in amino acids, proteins, enzymes, and fatty acids. This 
functional group has important biological activities; it can be easily masked into alkyl or aryl 
esters and can be regenerated in the body during metabolism. This feature enhances the 
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lipophilicity of phenothiazine derivatives to selectively concentrate more in malignant tissues, 
while leaving the chromophore intact for irradiation in PDT. The excess alkyl esters in the body 
can be readily cleaved by esterase in blood, liver, and other body tissues to ensure their 
decomposition in the body at a faster rate than those present in malignant tissues. Moreover, 
photosensitizers bearing carboxylic groups and hydroxy groups have been reported in literature 
to be non-toxic (Asmiyenti et Al. 2012), 41 therefore we expect the new derivatives to be 
nontoxic. 
The specific positions of certain side groups on the phenothiazinium ring make them 
attractive as organic linkers for metal organic frameworks (MOF’s). Binding of the metal ions to 
organic linkers which are not too large and too small such as the three core aromatic rings of 
phenothiazine will increase the robustness and right pore aperture for metal organic frameworks 
synthesized from our derivative for potential application in the energy industry. MOF’s with the 
right size of their surface pores can be used gas capture and storage for hydrogen gas alongside 
drug delivery by storing drug materials in their pores and discharging them to targeted sites in 
the human body. 
We further anticipate these derivatives to effectively inject electrons into conduction 
bands in DSSC when excited by sunlight light. This feature is a key characteristic of the dyes 
employed in DSSC. These derivatives with two carboxylic acid groups directly attached to the 
phenothiazinium ring are expected to counter the electron withdrawing effect of the electron- 
deficient sulfur cation. These derivatives are expected to effectively bind to the surface of 
titanium oxide (TiO2) through the carboxylic groups. This binding can improve the efficiency of 
DSSC. 
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CHAPTER 2 
RESULTS AND DISCUSSIONS 
           Various simple monosubstituted carboxylic acid derivatives of phenothiazine have been 
reported in literature, which have shown remarkable antimicrobial activities. A number of these 
derivatives have also been tested in PDT and DSSC and have proved to be efficient 
photosensitizing agents in these fields.11, 16, 17, 33, 40 In all these reports, mono-substituted 
carboxylic acid derivatives were more successfully synthesized and found to be of low toxicity in 
PDT applications.41, 48 
            However, these mono substituted derivatives were difficult to purify and were of low 
percentage yields. 48 We observed similar drawbacks in our attempts to synthesize 3,7-
phenothiazinium dicarboxylic acid (PTZ dicarboxylic acid), Schemes 5-7.  All compounds that 
were synthesized in this work were characterized by NMR and IR spectroscopy. TLC was used 
for monitoring the progress of reactions and checking the purity of products.  
 
Scheme 5:  Proposed synthetic route for the PTZN dicarboxylic acid from unprotected 
phenothiazine using Grignard reaction. 
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Scheme 6: Proposed synthetic route for the PTZN dicarboxylic acid from protected 
phenothiazine using Grignard reaction. 
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Scheme 7: Proposed synthetic route of the PTZN dicarboxylic acid using Sandmeyer reaction. 
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Synthesis of phenothiazine-5-ium tetra iodide hydrate (PTZN) 
          This compound was synthesized using a modified procedure from the one reported by 
Wainwright (Reaction 1) upon addition of a solution of iodine to phenothiazine over a period of 
1 hour (Reaction 1).12, 17 A dark blue product was obtained in 72 % yield, with physical data 
consistent with that reported in literature.  
          Initial TLC analysis of the product in chloroform/ methanol mixture (3:1, v/v) showed 
three spots of different Rf values and colors. One of the spots was colorless with Rf = 0.550 
comparable to that of phenothiazine starting material (this spot was oxidized to a blue compound 
upon exposure of the TLC plate to air).  The TLC indicated that the reaction was incomplete. 
          A second TLC analysis of the product, after washing of the crude product thoroughly with 
chloroform (CHCl3), showed only two spots. The spot which disappeared after washing with 
excess chloroform is believed to be from excess iodine used as an oxidizing agent in the reaction.  
The remaining two spots were separated by column chromatography to give 0.157 g (72%) as 
dark blue to green product. The product (PTZN) had a higher Rf (0.702) compared to 
phenothiazine (0.553). 1H NMR analysis of this compound showed two doublets and two triplets. 
There was no singlet peak for N-H as seen in phenothiazine; indicating the oxidation of the 
aromatic ring (ref. to spectra in Appendix I 1 and I 2).   
 
   (Reaction 1) 
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Synthesis of 3,7-dibromophenothiazinium perbromide (2) 
          This compound was prepared by suspending phenothiazine in an excess amount of 
bromine in glacial acetic acid (Reaction 2). The dark red solution was stirred for 16 hours at 
room temperature, and then treated with an adequate amount of sodium sulfite to reduce the 
excess bromine.    
       A green solid that precipitated out was obtained by filtration, and further recrystallized from 
a mixture of ethyl acetate/hexane (8:1, v/v), to give (2) in 75 % yield. TLC analysis of the 
product (mp = 263-265 oC) showed one spot which has a relatively lower Rf (0.535) value 
compared to phenothiazine.  
        The physical appearance of the product was consistent with literature reports.46 Proton 
NMR analysis of the product showed two doublets and a singlet at 7.360 (d, J =8.4 Hz), 7.778 
(d, J =8.0 Hz), and 8.199 (s) respectively (refer to the spectrum in Appendix A). The absence of 
a second singlet peak (N-H) in this product comparable to phenothiazine indicates the product is 
in the oxidized as seen in Reaction 1.   The counter ion reported for this oxidized product is the 
tribromide.46 
                          
(Reaction 2) 
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Synthesis of N-acetyl phenothiazine (5) 
         Compound 5 was prepared by refluxing phenothiazine in acetic anhydride for 3-5 hours 
(Reaction 3). After washing with acetone, the product was obtained in 95% yield as a yellow 
solid, (mp 197-198 oC, lit. 196-197 oC) .22  
           TLC analysis of the product after recrystallization from acetone gave a single spot which 
is a little higher in Rf value compared to the starting phenothiazine compound. 
1H NMR 
spectrum of the product was consistent with that reported in literature,23 which showed two 
triplets and two doublets in the aromatic region, and one singlet in the aliphatic region (refer to 
the spectra in Appendix B1 and B2).  13C NMR of the product showed 6 peaks, in the aromatic 
region, 1 in the alkane region and 1 peak in the amide region confirming the protection of the 
aromatic ring. 
                         
  (Reaction 3) 
 
Synthesis of N-acetyl-3,7-dibromophenothiazine (6) 
           Synthesis of this compound was carried out under two different conditions (Reaction 4). 
First, the amide derivative (N-acetylphenothiazine, 5) was stirred for 16 hrs, at room temperature 
in glacial acetic acid, with excess bromine. A green product (6) was obtained, but of ~ 10%yield.      
The second reaction which involved refluxing (110-120 oC) compound 5 with bromine in glacial 
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acetic acid gave 62% yield of the product (pale green in appearance). The product obtained by 
this approach was found to be the unprotected 3,7-dibromophenthiazinium,  6B (mp 206-208 
oC). The melting point of 6B is different from compound 2. This may be due to the difference in 
counter ion of this product (6B) compared to compound 2. Reported work by Plater and co-
workers indicates that the counter ion in this product is either a mono bromide (Br-) or a 
tribromide (Br3
-) ion.46 
            TLC analysis of the product showed one spot indicating the compound is pure.  1H NMR 
of this product showed only three signals, with all of them in the aromatic region: a doublet of 
doublet, a doublet, and a singlet (refer to the spectrum of Appendix H1and H2). Lack of CH3 
signal in the aliphatic region of the spectrum indicates that de-protection and oxidation of 
phenothiazine to phenothiazinium took place. When the reaction is conducted at 70-80 ºC 
(instead of refluxing) a dark-purple product is isolated alongside 6B.  1H NMR of this side 
product shows two doublets in the aromatic region and a singlet in the aliphatic region (for the 
protecting acetyl group).  The melting point value of the purple product is 227-229 oC. This 
product is could be the tetra bromophenothiazine amide (6A) resulting from poly bromination of 
the compound 5 as the reaction progressed. 
                   
   (Reaction 4) 
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Synthesis of phenothiazin-3,7-dicarboxylic acid (4) and  
N-acetyl-3,7-phenothiazinedicarboxylic acid (8) 
           We attempted to synthesize compound 4 and 8 starting with 2 (Reaction 2) and 6B 
(Reaction 4). A series of trials failed to yield the expected products (4 and 8). One major 
challenge was the insolubility of starting materials in diethyl ether (the solvent that is commonly 
used in the Grignard reaction).  One starting material (6B) was quite soluble in THF when 
heated, but failed to react with Mg to form the Grignard intermediate.  Other trials using t-butyl 
methyl ether and 1,4-dioxane as solvents experienced the same challenges mentioned above. 
 
Synthesis of 3,7-dinitrophenothiazine (10) 
           In this procedure, the nitration of phenothiazine was done using sodium nitrite in a 
mixture of chloroform and acetic acid to give 70% yield of 10 as a brown solid (Reaction 5). 
TLC analysis of the brown product (chloroform-methanol, 3:1, v/v as eluent) gave only one spot 
(Rf =0.667).  
1H NMR of the product showed three signals in the aromatic region; a doublet of 
doublet, two doublets, and a singlet in the alkane region. 13C NMR of the product showed the 
expected 6 peaks in the aromatic region and two additional peaks in the alkane region and   
amide region. These peaks may be from DMF contamination of the product or acetate counter 
ions from acetic acid used in the reaction (ref. to spectra in Appendix C1, C2, C3 and C4). IR 
analysis showed a medium sharp peak around 3400 cm-1 (N-H) indicating a secondary nitrogen. 
The melting point (220-222 oC) value of the product indicates that the product is pure.  
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           Several other attempts were made in synthesizing this derivative via other routes. The first 
attempt involved nitrating phenothiazine amide (5) using sulfuric acid and nitric acid in 1:1(v/v) 
and 1:3(v/v) ratios, respectively, as nitrating reagents. The reaction yielded an orange solid, 
which is reported as 3,7-dinitrophenothiazin-5-oxide in literature.48 This formation of this 
product is a result of the high oxidative nature of the concentrated nitric acid and the high 
affinity of oxygen by sulfur.  Another attempt using sodium nitrite in the presence of 
hydrochloric acid in situ yielded an intractable reddish brown precipitate; no further attempts 
were made to characterize this product.  
 
               
 (Reaction 5) 
 
Synthesis of N-acetyl-3,7-dinitrophenothiazine (11) 
           This synthesis involved the protection of the phenothiazine ring through amide bond 
formation which is carried out at reflux temperatures between 120-130 ºC. The product obtained 
was a yellow solid in 71 % yield (mp 213-214 oC), after purification by column chromatography 
and recrystallization from acetone (Reaction 6). TLC analysis of the yellow product 
(chloroform-methanol, 3:1, v/v as eluent) gave only one spot of Rf (0.645) which was lower than 
compound 10.  1H NMR of 11 showed four signals; a doublet of doublet and two doublets (all 
corresponding to the aromatic protons between 7-8.5 ppm) and a singlet for the acetyl group in 
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the alkane region (ref. to spectra in Appendix D1 and D2). Integrations of these individual peaks 
showed a 1:1:1 ratio for protons in the aromatic region and 1.5 for the singlet in the alkane 
region; corresponding to 2H for each of the aromatic signals and 3H for the acetyl group. 13C 
NMR gave 8 peaks as expected with the characteristic amide carbon and alkane carbon at 
168.696 (C=O) and 23.397 (CH3) ppm respectively (ref to spectra in appendix D3 and D5).  IR 
spectrum (ref. to spectrum at Appendix D5) showed a peak at 1710 cm-1 for C=O stretching in 
the acetyl group.  
          Other attempts which involved nitrating the amide derivative (5) with nitric acid (HNO3) 
in the presence of sulfuric acid were not successful. This could be due to the protonation of the 
carbonyl bond (C=O) or the de-protection of the ring via amide hydrolysis which readily occurs 
in acidic medium. Another reason could be due to the mono nitration product which is formed in 
low yield that may affect the overall yield of the product. 
 
  
   (Reaction 6) 
 
Synthesis of N-acetyl-3,7-diaminophenothiazine (12) 
           This product was isolated as a blue solid from Reaction 7 below. TLC analysis of the 
product gave one spot with a higher Rf (0.688) value compared to compound 11. The melting 
point value of the product was 172-174 ºC; indicating the isolated product is pure. 1H NMR 
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showed four peaks; a doublet-doublet and two other doublets, all corresponding to the aromatic 
protons in the regions of 7-8.5 and two characteristic singlet peaks for the acetyl group in the 
alkane region and the amino group (-NH2) at 5-6 ppm, respectively (ref. to spectra at Appendix 
E1 and E2). The singlet peak for the NH2 was broad. Integrations of these individual peaks 
showed a 1:1:1 ratio for protons in the aromatic region and 1.5 and 2 for the singlet at 2 ppm and 
5.6 ppm for the -CH3 and -NH2 respectively. IR analysis also showed a stretching frequency 
around 1710 cm-1 for C=O and 3350 cm-1 for the two peaks of the primary amine resulting from 
the reduction of the nitro groups (ref. to spectrum at Appendix E3).  
           Other attempts using tin (II) chloride in hydrochloric acid yielded less than 13% of the 
product, mixed with unreacted amounts of compound 11. This could be a result of the 
protonation of the carbonyl group by HCl which may undergo further hydrolysis of the amide.            
 
                   
 (Reaction 7) 
 
Conversion of thionine acetate and N-acetydiaminophenothiazine (12) into thionine chloride (15) 
           This derivative was synthesized using two different starting materials (thionine acetate or 
thionine amide) under different conditions as shown in Scheme 8. The first approach which 
involves the use of thionine amide (12) was refluxed in hydrochloric acid at temperatures 
 46 
 
between 110-120 ºC for 2-3 hrs (Scheme 8b). The product precipitated as a blue solid upon 
cooling. 
           The second approach using thionine acetate as the starting material was carried out at 
room temperature.  This reaction proceeded readily at room temperature (Scheme 8a). 43 TLC 
analysis of the product using chloroform/ methanol mixture (3:1, as eluent) showed a single spot 
of Rf (0.698). 
13C NMR spectrum showed six peaks corresponding to carbons in the aromatic 
region (ref. to spectra at Appendix F1 and F2). 
 
 
 
Scheme 8a: Proposed mechanism for the conversion of thionine acetate into thionine chloride.43 
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Scheme 8b: Proposed mechanism for the conversion of thionine amide into thionine chloride.43 
 
Synthesis of 3,7-phenothiaziniumdinitrile (14) 
           The synthesis of this derivative follows a two-step synthetic pathway. The first step 
involved the formation of diazonium salts from thionine chloride or thionine amide and 
converting it to the nitrile derivative. The diazonium salt is prepared in-situ by dissolving the 
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amino derivatives (12 or 15) in dilute hydrochloric and stirring in ice. The reaction was carried 
out at a constant temperature between 0-4 ºC in order to prevent the decomposition of the 
diazonium salt through coupling.  
           The second step involved the conversion of the intermediate diazonium salt into the nitrile 
upon reaction with cuprous cyanide, to give a dark solid as shown in Scheme 9.  IR analysis of 
the solid shows a medium sharp peak for the CN stretching between 2200-2400 cm-1 and medium 
sharp peak for C=C around 1600 cm-1 (ref spectrum at Appendix G5).    1H NMR showed a 
doublet of doublets, a doublet, and two singlets in the aromatic region. There was no singlet peak 
in the alkane region even when thionine amide is used in this reaction. This may be due to the 
simultaneous de-protection of the ring through hydrolysis as the diazotation reaction proceeds 
(ref. to spectra at Appendix G1 and G2).13C NMR analysis showed more than 7 peaks as 
expected in the product (ref. to spectra at Appendix G3 and G4). The extra peaks could be 
resulting from coupling products that are common in Sandmeyer’s reaction. Another reason 
could be due to the formation of monocyanide side product resulting from the reaction. 
         Other attempts using potassium cyanide in the second step of the reaction also yield low 
amounts of the dark product. 
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Scheme 9a: Conversion of N-acetyl diaminophenothiazine into the phenothiaziniumdinitrile 
derivative. 
 
 
 
Scheme 9b: Conversion of thionine chloride into the phenothiaziniumdinitrile derivative. 
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CHAPTER 3 
EXPERIMENTAL 
Materials and General Method 
           All reactions proceed from phenothiazine which was commercially obtained from Sigma 
Aldrich. Every chemical reagent and solvent listed were also obtained from commercial sources 
and used without further purification unless stated.  
           The compounds synthesized were characterized by 1H NMR and IR spectroscopy. All 
NMR spectra were recorded on a JEOL-NMR Eclipse-400 MHz spectrophotometer. The 
different chemical shifts of all peaks are quoted in parts per million (ppm) using the high-
frequency position conversion, and the coupling constants value (J) are reported in Hz. The 
splitting patterns of resonance were described as follows: singlet (s), doublet (d), doublet of 
doublet (dd), triplet (t), quartet (q), and multiplet (m).  All IR spectra were recorded from 
Shimadzu 1R Prestige-21 FT-IR spectrometers. Melting points of synthesized compounds were 
measured without correction from a Cambridge Melt-Temp device. Chromatographic techniques 
(thin layer chromatography and column chromatography) were also carried out in order to obtain 
the pure form of synthesized compounds. 
 
 
Experimental Procedures 
Synthesis of phenothiazin-5-ium tetra iodide hydrate (PTZN) 
           A solution of iodine (0.83 g, 3.3 mmol) in 19 mL of chloroform was added drop wise to a 
solution of phenothiazine (0.21 g, 1.1 mmol) in 7.5 mL of chloroform. After the addition was 
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complete, the solution was stirred for half an hour in an ice bath, the resulting mixture was 
filtered and the precipitate was washed with 20 mL of chloroform until filtrate was colorless and 
dried under reduced pressure to give 0.157 g (72% yield) of the desired product. 17 
NMR (DMSO-d6): δH = 6.231 (d, 2H, J = 8.4 Hz), δH= 6.843 (t, 2H), δH = 6.949 (t, 2H), δH = 
7.029 (d, 2H, J = 7.6 Hz) 
 
Synthesis of 3, 7-dibromophenothiazin-5-ium perbromide (2) 
           Phenothiazine (0.20 g, 0.20 mmol) was suspended in 7.2 mL of glacial acetic acid.  
Br2 (1.5 mL, 0.063 mol) in 20 mL of glacial acetic acid was added all at once to the reaction 
mixture with vigorous stirring, stirring continued for 24 more hours at room temperature. The 
reaction was then cooled with an ice bath and 0.25 g (0.50 mmol) of sodium sulfite (Na2SO3) was 
added to the reaction mixture.46  About 1-2 mL of water was added to the reaction mixture to 
form a deep-violet color within three hours of stirring.  A 1 M sodium hydroxide (NaOH) 
aqueous solution was added to the solution with stirring for 30 minutes. A dark-purple solid 
precipitated out of solution which was filtered off and stirred in excess hot ethyl acetate/hexane 
mixture (1:8, v/v).49  0.23 g (88% yield, mp 263-265 ºC) of the product was obtained as a green 
powder which was filtered off and dried under vacuum. 
NMR (DMSO-d6: δH = 7.360 (d, 2H, J = 8 Hz), δH= 7.778 (d, 2H, J = 8.4 Hz), δH= 8.199 (s, 2H) 
ppm.  
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Synthesis of 1-phenothiazin-10-ylethanone (5) 
           Phenothiazine (1 g, 5 mmol) was suspended in 10 mL of acetic anhydride. The mixture 
was refluxed for 3-5 hrs and monitored with TLC. The warm solution was allowed to cool to 
room temperature and further cooled in an ice bath. A pale yellow solid precipitated, which was 
filtered and recrystallized from acetone to produce 1.220 g (92.5% yield, mp 197-198 ºC) of the 
product.  
NMR (DMSO-d6): δH = 7.550 (d, 2H, J= 6.4 Hz), δH= 7.641(d, 2H, J = 8 Hz), δH= 7.403 (t, 2H, J 
= 6.8 Hz), δH= 7.308 (t, 2H, J =6.4 Hz), δH= 2.150 (s, 3H); δC = 168.982 (C=O), δC = 139.228 
(ArC), δC = 132.527 (ArC), δC = 128.416 (ArC), δC = 128.018 (ArC), δC = 127.827 (ArC), δC = 
127.544 (ArC), 23.271 (CH3) ppm. 
IR (νmax/cm-1): 1700 (s, C=O), 1600 (w, C=C), 1470 (m, C=C) 
 
Synthesis of N-acetyl-3,7-dibromophenothiazine (6) 
Approach 1: 
          Compound 5 (0.9637 g, 3.9 mmol) was suspended in 38 mL of glacial acetic acid and 
stirred for 10 minutes. To the stirring mixture, 0.64 mL (12 mmol) Br2 in 38 mL of glacial acetic 
acid was slowly added to the reaction mixture and stirred for 16 h at room temperature. The 
reaction was cooled with an ice bath and 1.25 g (9.9 mmol) of Na2SO3 was added to the reaction 
mixture. By adding a little water (1.0 mL), a deep-violet color formed within three hours. After 
the addition of a solution of 1% of KOH aqueous solution, a pale green solid formed which was 
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filtered. The solid was washed with cold isopropanol to give 0.410 g (29 % yield) of the titled 
product. 
Approach 2: 
          Compound 5 (0.3 g, 1.24 mmol) of was suspended in 12 mL of glacial acetic acid and 
stirred for 10 minutes. To the stirring mixture, 0.2 mL (3.95 mmol) Br2 in 38 mL of glacial acetic 
acid was slowly added to the reaction mixture and maintained at reflux for 16 hrs at temperatures 
between 70-80 ºC and 120 ºC respectively, while monitoring with TLC. A purple precipitate was 
obtained from reaction conditions of 70-80 ºC temperature and a pale green solid was obtained 
from reaction conditions at 120 ºC. After cooling the solution to room temperature and further on 
ice, the precipitates were filtered and washed with cold isopropanol and dried to give 0.450 g (65 
% yield) of the purple (6A) product and 0.320 g (72.5 % yield, mp 206-208 ºC) of  the pale green 
(6B) product. 
 
Grignard synthesis of phenothiazin-3,7-dicarboxylic acid (4) and  
N-acetyl-3,7-phenothiazinedicarboxylic acid (8) 
          Anhydrous diethyl ether (0.5 mL) was added to 50 mg (2 mmol) of magnesium powder in 
a dry test tube sealed with a septum. In a second dry test tube, 1 mL of anhydrous diethyl ether 
was added to 100 mg of 3,7-dibromophenothiazine (2) using the same syringe. About 0.1 mL of 
the dibromophenothiazine-ether mixture was added dropwise to the magnesium-ether mixture 
with a syringe and mixed by shaking the testube. The septum was pierced with a clean syringe 
for pressure relief while the reaction progressed vigorously. The remaining 
dibromophenothiazine-ether mixture was added dropwise when the reaction is less vigorous until 
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all the mixture was exhausted. A magnetic stirrer was added to the reaction tube and stirred until 
only a small amount of the metal was left. While the reaction progressed, the volume of the ether 
was checked periodically to make sure the volume has not decreased and a little more ether was 
added when the volume was low. Since the Grignard reagent deteriorates on standing, the next 
step was done immediately; the solution was separated from the magnesium metal left. 
           Carbon dioxide gas was bubbled through the Grignard solution for about 20 to 30 minutes 
in a dry test tube sealed with a septum. The septum was pierced with a syringe to relieve the 
pressure built up in the tube. To the pale yellow viscous solution formed, 3 ml of 3 M 
hydrochloric acid was added. The aqueous layer was removed and discarded.  The ether layer is 
then shaken with 1mL of water and left to stand for a few minutes. The aqueous layer was once 
again removed and discarded. The product was extracted from the ether layer with 3 x 1 mL of 3 
M aqueous sodium hydroxide solution. The ether layer was discarded and the clear solution was 
heated briefly to drive off the excess dissolved ether. 3 M hydrochloric acid was added to the 
mixture until the solution tested acidic. The mixture was cooled on ice and the product collected 
by vacuum filtration. The solid was recrystallized from water. These steps in Grignard synthesis 
were also carried out on the 10-acetyl-3,7-dibromophenothiazine. 
 
Synthesis of 3,7-dinitrophenothiazine (10) 
           Sodium nitrite (0.2 g, 3 mmol) was added to a mixture of phenothiazine (0.2 g, 1 mmol), 
0.4 mL of acetic acid and 1mL of dichloromethane (CH2Cl2) and stirred for 10 minutes. An 
additional 0.4 mL of acetic acid, 1 mL of dichloromethane, and sodium nitrite (0.2 g, 3 mmol) 
were added to the mixture.  1.2 mL of acetic acid was further added to break the thick reaction 
 55 
 
mixture and stirred for 3 to 5 hours.47 The solid suspension was filtered out and washed with 1 
mL of ethanol, followed by 1 mL of water and finally 1 ml of ethanol to give a purple-brown 
solid. The residue was stirred in a minimum volume (5 mL) of hot DMF (Dimethylformamide),47 
and allowed to cool before filtering out to give 0.1744 of the product (70 % yield, mp 220-222 
ºC) which was washed with another 3 mL of ethanol and dried under vacuum.  
NMR (DMSO-d6): δH=6.835 (d, 2H, J = 8.8 Hz), δH= 7.729 (d, 2H, J = 2.4 Hz), δH= 7.845 (dd, 
2H, J = 6.4 Hz), δH = 1.830 (s, 3H); δC = 173.693 (C=O), δC =146.134 (ArC), δC = 142.868 
(ArC), δC = 125.304 (ArC), δC = 122.168 (ArC), δC = 117.194 (ArC), δC = 115.516 (ArC), δC = 
26.750 (CH3) ppm. 
IR (νmax/cm-1): 3400(s, N-H), 1510 and 1575 (m, N-O), 1600 (m, C=C) 
 
Synthesis of N-acetyl-3,7-dinitrophenothiazine (11) 
           A mixture of 3,7-dinitrophenothiazine (1 g, 3.45 mmol) and acetic anhydride (6 mL, 63.4 
mmol) were stirred in pyridine (10 mL) at reflux for 24 hrs. The warm solution was carefully 
poured over crushed ice and allowed to stand for a few minutes to form a precipitate. The 
precipitate formed was then filtered, dissolved in dichloromethane and dried over anhydrous 
sodium sulfate. The solution was filtered and concentrated to give a brown-orange solid which 
was purified by column chromatography (silica gel, 2:3 ethyl acetate and petroleum ether, loaded 
as dichloromethane solution) to give 0.8128 g (71 % yield, mp 213-214 ºC) of  the product.47 
 NMR (DMSO-d6): δH= 7.962 (d, 2H, J = 9.2 Hz), δH= 8.290 (dd, 2H, J =6.8 Hz), δH= 8.482 (d, 
2H, J = 2.4 Hz), δH= 2.250 (s, 3H); δC = 168.696 (C=O), δC = 146.317 (ArC), δC = 143.683 
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(ArC), δC = 133.520 (ArC), δC = 128.825 (ArC), δC = 123.904 (ArC),δC =123.568 (ArC) , δC = 
23.397 (CH3) ppm. IR (νmax/cm-1): 1700 (s, C=O), 1510 (s, NO), 1550 (w, NO) 
 
Synthesis of N-acetyl-3,7-diaminophenothiazine (12) 
           A mixture of 10-acetyl-3,7-dinitro-phenothiazine (0.3 g, 0.9 mmol), tin (II) chloride 
dihydrate (2.1195 g, 3 mmol), and ethanol (3 mL) was heated to reflux and stirred at this 
temperature for 5 hours.47 The mixture was then cooled to room temperature and poured over ice 
water. The pH was adjusted to 7 with 5% sodium hydrogen carbonate before the product was 
extracted with ethyl acetate (3 x 3 mL).47 The extracts were washed with brine and dried over 
anhydrous sodium sulfate, filtered, and concentrated to give 0.1890 g (77.4 % yield, mp 172-174 
ºC) of the product. 
NMR (DMSO-d6): δH= 5.234 (s, 4H), δH= 6.484 (dd, 2H, J = 6 Hz), δH= 6.618 (s, 2H), δ= 7.147 
(d, 2H, J = 8.4 Hz), δH= 2.010 (s, 3H) ppm. 
IR (νmax/cm-1): 3300 (m, NH), 1675 (s, C=O), 1600 (s, C=C), 2850 (w, CH) 
 
Conversion of thionine acetate and N-acetyl-3,7-diaminophenothiazine (12) into thionine            
chloride (15) 
           Two approaches were used in the synthesis of this phenothiazinium derivative using two 
different starting materials. In the first approach, 0.1 g (0.37 mmol) thionine amide (12) which is 
the starting material was hydrolyzed with a few mL of concentrated hydrochloric acid (HCl) for 
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2-3 hours by refluxing at 110 ºC. The hot solution was cooled to room temperature and further in 
ice to obtain 0.0882 g (90 % yield) of the product.  
           In the second approach, commercial thionine acetate (0.5 g, 1.74 mmol) was hydrolyzed 
by first dissolving in water, followed by the addition of a few mL of concentrated hydrochloric 
acid (HCl). This approach gave 0.4363 g (95 % yield) of the product which was blue in color. 
 NMR (DMSO-d6);
 δC 157.122 (ArC), δC =138.840 (ArC), δC = 135.206 (ArC), δC = 134.816 
(ArC), δC = 121.862 (ArC), δC = 107.792 (ArC) ppm 
IR (νmax/cm-1): 3307 (m, NH), 3000 (s, CH), 1602 (s, C=C), 1490 (s, C=C) 
 
Synthesis of 3,7-phenothiaziniumdinitrile (14) 
           Hydrochloric acid (5 mL, 6 M) was added to 0.1 g (0.35 mmol) of thionine chloride and 
stirred until all solids dissolved. The solution was left to cool in ice to 0 ºC.  0.2 g (2.89 mmol) of 
sodium nitrite in 5 ml of cold water was added dropwise until the reaction was complete. After 2-
3 hours of stirring with monitoring by TLC, a solution of 0.3 g (3.35 mmol) copper cyanide in 
3mL of hydrochloric acid (12 M) was added with continuous stirring for 2 hours. A dark-brown 
solid complex precipitated. The mixture was taken off the ice and left to stand for 10 minutes. It 
was then warmed to 40 oC at which point a vigorous reaction ensued (nitrogen gas evolution; 
separation of a solid and foaming). After reacting for half an hour, the mixture was heated on an 
oil bath for 10 minutes at 70 ºC and allowed to cool to room temperature and further in ice. The 
solid product was collected by filtration, washed with a few ml of cold water (2-3 mL) and 
stirred in cold ethanol. The solid was filtered off and dried to give 0.0719 g (66 % yield) of the 
titled product which was purple-brown. 
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NMR (DMSO-d6): δH = 8.825 (s), 7.905 (dd, 2H, J = 9.6 Hz), 7.273 (d, 2H, J = 9.2 Hz), 7.202 (s, 
2H); δC = 136.464 (ArC), δC = 135.730 (ArC), δC =135.164 (ArC), δC =133.799 (ArC), δC 
=133.057 (ArC), δC =130.710 (ArC), δC =125.571 (ArC), δC =125.059 (ArC), δC =123.216 (ArC), 
δC =119.821 (ArC), δC =118.850 (ArC) 
IR (νmax/cm-1): 3040 (w, CH), 2171 (m, CN), 1600 (s, C=C) 
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CHAPTER 4 
CONCLUSION 
           In this project, various derivatives of phenothiazine and phenothiazinium were 
synthesized, using commercially available phenothiazine (1).  These derivatives include: 3,7-
dibromophenothiazinium perbromide (2), N-acetyl phenothiazine (5), N-acetyl-3,7-
dibromophenothiazine (6),  3,7-dinitrophenothiazinium acetate (10), N-acetyl-3,7-
dinitrophenothiazine (11), N-acetyl-3,7-diaminophenothiazine (12), thionine chloride (15), and 
3,7-phenothiaziniumdinitrile (14). Synthesis of 3,7-phenothiazinium dicarboxylic acid was 
attempted using 1 and 15 as starting materials, as shown in schemes 4-6. 
           Synthesis of the dicarboxylic acid derivative via Grignard synthesis was not successful 
after several attempts. This method faced challenges of solubility of phenothiazinium dibromide 
in diethyl ether and t-butyl methyl ether. On the other hand, although solvents such as THF and 
1,4-dioxane could dissolve the  phenothiazinium dibromide, the Grignard reaction failed to yield 
the dicarboxylic acid. 
           Synthesis of the dicarboxylic acid from thionine chloride (15), via the Sandmeyer 
reaction, gave a number of intractable products; with none being the desired phenothiazinium 
dicarboxylic acid. The phenothiazinium dinitrile intermediate was difficult to purify; it’s 1H 
NMR showed aromatic impurities, resulting from unreacted starting material and some coupling 
products of the diazonium salt.   
           Future work would involve further purification of the dinitrile product. After purification 
the dinitrile could be hydrolyzed to the dicarboxylic acid derivatives. Synthesis of 
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phenothiazinium dicarboxylic acid can also be explored by other methods such as the 
Rosenmund Von Braun reaction. 
           After the synthesis and purification of phenothiazinium dicarboxylic acid it will be tested 
in photodynamic therapy (PDT). We will seek collaboration with scientists in the medical field 
for completing this part of this work. The new derivative will also be tested for applications in 
the dye sensitizing solar cells (DSSC), and in the synthesis of metal organic frameworks 
(MOF’s). 
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APPENDICES 
Appendix A: 1H NMR Spectrum for Compound 2 in DMSO-d6 
 
 
 
 68 
 
Appendix B1: 1H NMR Spectrum for Compound 5 in DMSO-d6 
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Appendix B2: 1H NMR Spectrum for Compound 5 in DMSO-d6 
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Appendix B3: 13C NMR Spectrum for Compound 5 in DMSO-d6 
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Appendix B4: 13C NMR Spectrum for Compound 5 in DMSO-d6 
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Appendix B5: IR Spectrum for Compound 5 
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Appendix C1: 1H NMR Spectrum for Compound 10 in DMSO-d6 
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Appendix C2: 1H NMR Spectrum for Compound 10 in DMSO-d6 
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Appendix C3: 13C NMR Spectrum for Compound 10 in DMSO-d6 
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Appendix C4: 13C NMR Spectrum for Compound 10 in DMSO-d6 
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Appendix C5: IR Spectrum for Compound 10 
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Appendix D1: 1H NMR Spectrum for Compound 11 in DMSO-d6 
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Appendix D2: 1H NMR Spectrum for Compound 11 in DMSO-d6 
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Appendix D3: 13C NMR Spectrum for Compound 11 in DMSO-d6 
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Appendix D4: 13C NMR Spectrum for Compound 11 in DMSO-d6 
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Appendix D5: IR Spectrum for Compound 11  
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Appendix E1: 1H NMR Spectrum for Compound 12 in DMSO-d6 
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Appendix E2: 1H NMR Spectrum for Compound 12 in DMSO-d6 
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Appendix E3: IR Spectrum for Compound 12  
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Appendix F1: 13C NMR Spectrum for Compound 13 in DMSO-d6 
 
 
 
 87 
 
Appendix F2: 13C NMR Spectrum for Compound 15 in DMSO-d6 
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Appendix F3: IR Spectrum for Compound 13  
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Appendix G1: 1H NMR Spectrum for Compound 14 in DMSO-d6 
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Appendix G2: 1H NMR Spectrum for Compound 14 in DMSO-d6 
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Appendix G3: 13C NMR Spectrum for Compound 14 in DMSO-d6 
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Appendix G4: 13C NMR Spectrum for Compound 14 in DMSO-d6 
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Appendix G5: IR Spectrum for Compound 14 
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Appendix H1: 1H NMR Spectrum for Compound 6B in DMSO-d6 
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Appendix H2: 1H NMR Spectrum for Compound 6B in DMSO-d6 
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Appendix I1: 1H NMR Spectrum for PTZN in DMSO-d6 
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Appendix I2: 1H NMR Spectrum for PTZN in DMSO-d6 
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